No surprise here: the Philadelphia Transportation Authority is suing
Gilead, maker of the expensive new hepatitis C drugs Sovaldi and
Harvoni, over the cost of those drugs. A course of Sovaldi, not
including drugs you might have to take in combination with it, as some
patients do, costs $84,000. Harvoni, which won FDA approval more
recently, costs $94,000.
not be surprised if we start seeing more suits over the drugs’ pricing,
including patient groups suing insurers over access to the drugs, and
groups with even less leverage when it comes to getting the drugs, like
The drugs are indeed expensive. I’ve reported on that in my series “At the Crossroads,” both in this story about why the drugs represent such a breakthrough for patients but such a conundrum for payers like Medicaid, and in this one about how health economists determine not just whether a treatment costs too much but whether it’s cost effective.